Table 3. Multivariate Cox regression analysis for EFS and OS.
| EFS | OS | |||||
|---|---|---|---|---|---|---|
| |
HR |
95% CI |
P-value |
HR |
95% CI |
P-value |
| Total cohort (n=315) | ||||||
| Mutation status, vs WT non-CBF | ||||||
| CBF | 0.31 | 0.19–0.49 | <0.01 | 0.09 | 0.03–0.25 | <0.01 |
| CEBPA-single | 0.47 | 0.24–0.91 | 0.02 | 0.60 | 0.29–1.26 | 0.18 |
| CEBPA-double | 0.33 | 0.14–0.76 | 0.01 | 0.30 | 0.09–0.94 | 0.04 |
| Age (+1 year) | 1.00 | 0.97–1.03 | 0.86 | 1.03 | 0.99–1.07 | 0.17 |
| WBC (⩾50 000) | 1.81 | 1.29–2.55 | <0.01 | 1.50 | 0.96–2.33 | 0.07 |
| Normal karyotype cohort (n=62) | ||||||
| Mutation status, vs WT | ||||||
| CEBPA-single | 0.54 | 0.22–1.33 | 0.18 | 0.88 | 0.31–2.47 | 0.81 |
| CEBPA-double | 0.28 | 0.08–0.95 | 0.04 | 0.49 | 0.11–2.17 | 0.35 |
| Age (+1 year) | 0.95 | 0.89–1.02 | 0.14 | 0.94 | 0.86–1.02 | 0.13 |
| WBC (⩾50 000) | 2.05 | 1.00–4.22 | 0.05 | 1.34 | 0.55–3.29 | 0.52 |
Abbreviations: CBF, core-binding factor; CEBPA, CCAAT/enhancer-binding protein alpha; CI, confidence interval; EFS, event-free survival; HR, hazard ratio; OS, overall survival; WBC, white blood cell count; WT, wild type.